Wallbox N.V. (WBX)
NYSE: WBX · Real-Time Price · USD
4.830
-0.340 (-6.58%)
Aug 1, 2025, 4:00 PM - Market closed
CTI BioPharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2020 |
| 147.98 | 163.94 | 143.77 | 144.19 | 71.58 | 19.68 | Upgrade | |
Revenue Growth (YoY) | -11.73% | 14.03% | -0.29% | 101.44% | 263.77% | 145.34% | Upgrade |
Cost of Revenue | 100.18 | 110.17 | 96.87 | 86.11 | 44.49 | 10.61 | Upgrade |
Gross Profit | 47.8 | 53.78 | 46.9 | 58.07 | 27.09 | 9.07 | Upgrade |
Selling, General & Admin | 64.96 | 78.1 | 93.94 | 116.2 | 37.56 | 11.44 | Upgrade |
Other Operating Expenses | 44.66 | 45.2 | 31.47 | 61.81 | 34.62 | 6.23 | Upgrade |
Operating Expenses | 149.36 | 161.18 | 153.85 | 196.91 | 80.67 | 20.05 | Upgrade |
Operating Income | -101.56 | -107.4 | -106.94 | -138.84 | -53.57 | -10.99 | Upgrade |
Interest Expense | -20.58 | -21.87 | -15.13 | -4.98 | -6.24 | -0.92 | Upgrade |
Interest & Investment Income | 0.34 | - | - | - | 0.06 | 0.01 | Upgrade |
Earnings From Equity Investments | - | - | - | -0.33 | - | -0.25 | Upgrade |
Currency Exchange Gain (Loss) | 8.68 | -4.04 | 1.47 | -3.62 | 1.03 | -0.07 | Upgrade |
Other Non Operating Income (Expenses) | 0.38 | -0.72 | 6.71 | 82.51 | -94.7 | -0.1 | Upgrade |
EBT Excluding Unusual Items | -112.73 | -134.03 | -113.9 | -65.25 | -153.42 | -12.31 | Upgrade |
Gain (Loss) on Sale of Investments | 1.83 | 1.93 | 1.13 | -2.47 | 0.01 | - | Upgrade |
Asset Writedown | -23.97 | -26.42 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | -72.17 | - | Upgrade |
Pretax Income | -132.51 | -158.52 | -112.77 | -67.73 | -225.58 | -12.31 | Upgrade |
Income Tax Expense | -4.48 | -6.72 | -0.7 | -4.93 | -1.81 | -0.91 | Upgrade |
Earnings From Continuing Operations | -128.03 | -151.79 | -112.07 | -62.8 | -223.78 | -11.4 | Upgrade |
Minority Interest in Earnings | 2.81 | 2.81 | 0 | - | - | - | Upgrade |
Net Income | -125.22 | -148.98 | -112.07 | -62.8 | -223.78 | -11.4 | Upgrade |
Net Income to Common | -125.22 | -148.98 | -112.07 | -62.8 | -223.78 | -11.4 | Upgrade |
Shares Outstanding (Basic) | - | 12 | 9 | 8 | 6 | 5 | Upgrade |
Shares Outstanding (Diluted) | - | 12 | 9 | 8 | 6 | 5 | Upgrade |
Shares Change (YoY) | - | 23.21% | 14.88% | 44.92% | 22.87% | 29.17% | Upgrade |
EPS (Basic) | - | -12.89 | -11.94 | -7.69 | -39.70 | -2.49 | Upgrade |
EPS (Diluted) | - | -12.89 | -11.94 | -7.69 | -39.70 | -2.49 | Upgrade |
Free Cash Flow | - | -59.78 | -76.34 | -174.09 | -80.34 | -15.77 | Upgrade |
Free Cash Flow Per Share | - | -5.17 | -8.13 | -21.31 | -14.25 | -3.44 | Upgrade |
Gross Margin | 32.30% | 32.80% | 32.62% | 40.27% | 37.85% | 46.07% | Upgrade |
Operating Margin | -68.63% | -65.51% | -74.38% | -96.29% | -74.84% | -55.83% | Upgrade |
Profit Margin | -84.62% | -90.87% | -77.95% | -43.55% | -312.63% | -57.95% | Upgrade |
Free Cash Flow Margin | - | -36.46% | -53.10% | -120.74% | -112.23% | -80.14% | Upgrade |
EBITDA | -88 | -93.95 | -97.69 | -119.95 | -45.09 | -8.61 | Upgrade |
EBITDA Margin | -59.47% | -57.31% | -67.95% | -83.19% | -62.99% | -43.74% | Upgrade |
D&A For EBITDA | 13.56 | 13.45 | 9.25 | 18.89 | 8.48 | 2.38 | Upgrade |
EBIT | -101.56 | -107.4 | -106.94 | -138.84 | -53.57 | -10.99 | Upgrade |
EBIT Margin | -68.63% | -65.51% | -74.38% | -96.29% | -74.84% | -55.83% | Upgrade |
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.